Evaluation of the germline single nucleotide polymorphism rs583522 in the TNFAIP3 gene as a prognostic marker in esophageal cancer

• Published in: Cancer genetics Vol. 208; no. 12; pp. 595 - 601
• Main Authors: Ghadban, Tarik, Schmidt-Yang, Magdalena, Uzunoglu, Faik G, Perez, Daniel R, El Gammal, Alexander T, Miro, Jameel T, Wellner, Ulrich, Pantel, Klaus, Izbicki, Jakob R, Vashist, Yogesh K
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2015
• Subjects: Biomarkers, Tumor - genetics; DNA-Binding Proteins - genetics; Esophageal cancer; Esophageal Neoplasms - diagnosis; Esophageal Neoplasms - epidemiology; Esophageal Neoplasms - genetics; Esophageal Neoplasms - mortality; Female; Hematology, Oncology and Palliative Medicine; Humans; Intracellular Signaling Peptides and Proteins - genetics; Kaplan-Meier Estimate; Male; Medical Education; Middle Aged; Nuclear Proteins - genetics; Polymorphism, Single Nucleotide - genetics; Prognosis; Protein A20; Retrospective Studies; Single nucleotide polymorphism; TNFAIP3; Tumor Necrosis Factor alpha-Induced Protein 3; TNFAIP3; Protein A20; Prognosis; Single nucleotide polymorphism; Esophageal cancer
• ISSN: 2210-7762; 2210-7770
• DOI: 10.1016/j.cancergen.2015.09.008

Most esophageal cancer patients die because of disease relapse, hence an accurate prognosis of disease relapse and survival is essential. Genetic variations in cancer patients may serve as important indicators. Three genotypes (GG, AG, and AA) are displayed by the single nucleotide polymorphism (SNP) rs583522, which maps to the TNFAIP3 gene on chromosome 6. Evaluation of the potential prognostic value of the TNFAIP3 -SNP in esophageal cancer (EC) was the aim of this study. A total of 158 patients underwent complete surgical resection of the esophagus for EC. None of them received any neoadjuvant or adjuvant treatment. Peripheral blood was sampled, and genomic DNA was extracted from leukocytes before each operation. Clinicopathologic parameters, tumor cell dissemination in bone marrow, and clinical outcome were correlated with the TNFAIP3 -SNP. A-allele carriers showed advanced tumor stages compared with those of homozygous G-allele carriers ( P  <   0.001). Patients with an A-allele genotype (AA or AG) were significantly more likely to experience a relapse ( P  =   0.003). Survival analysis (log-rank test) revealed a significant difference in overall survival between the three groups ( P  = 0.039); however, none of the genotypes was identified as a disease stage–independent prognostic marker. In conclusion, TNFAIP3 -SNP stratifies patients into different risk groups; however, it could not be identified as an independent prognostic marker.